NASDAQ:BCLI

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

Brainstorm Cell Therapeutics logo
$0.76 -0.08 (-9.60%)
As of 11/20/2026 03:47 PM Eastern

About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)

Advanced

Key Stats

Today's Range
$0.75
▼
$0.83
50-Day Range
$0.76
▼
$1.06
52-Week Range
$0.46
▼
$1.69
Volume
18,215 shs
Average Volume
19,835 shs
Market Capitalization
$11.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BrainStorm Cell Therapeutics is a biotechnology company focused on developing cell therapies for neurodegenerative diseases. Its lead program, NurOwn, is an investigational treatment designed to use a patient’s own bone marrow-derived mesenchymal stem cells, modified to produce neurotrophic factors that may support nerve cells.

The company has primarily studied NurOwn for amyotrophic lateral sclerosis (ALS). The therapy has been evaluated in clinical trials, including a Phase 3 study; it is investigational and has not been established as an approved treatment.

Founded in 2000, BrainStorm Cell Therapeutics conducts clinical development activities in the United States and has also been associated with research and development in Israel.

AI Generated. May Contain Errors.

Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCLI Stock News Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Headlines

BCLI Stock Analysis - Frequently Asked Questions

Brainstorm Cell Therapeutics' stock was trading at $0.5530 on January 1st, 2026. Since then, BCLI stock has increased by 37.3% and is now trading at $0.7594.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) released its quarterly earnings results on Monday, November, 16th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04.

Brainstorm Cell Therapeutics's stock reverse split on the morning of Tuesday, October 1st 2024.The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Plug Power (PLUG), GE Aerospace (GE), AbbVie (ABBV), Alibaba Group (BABA) and Bank of America (BAC).

Company Calendar

Last Earnings
11/16/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BCLI
CIK
1137883
Fax
N/A
Employees
19
Year Founded
2004

Profitability

EPS (Trailing Twelve Months)
($1.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.62 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-519.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.21
Quick Ratio
0.21

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.36) per share
Price / Book
-0.56

Miscellaneous

Outstanding Shares
14,809,000
Free Float
8,742,000
Market Cap
$11.25 million
Optionable
Optionable
Beta
0.35

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:BCLI) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners